Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone in Degenerative Thoracic Aortic Aneurysm
NCT07483177Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in thoracic aortic aneurysm (TAA) comparing Spironolactone with Placebo (2 arms). Primary endpoint: Carotid-femoral pulse wave velocity at 6 months. Started May 2026; status: recruiting.
02
Drugs
spironolactone
03
Conditions
thoracic aortic aneurysm (TAA)
Beyond the preview
Go deeper on NCT07483177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07483177.